Dina Jiesisibieke | Reproductive Health | Best Researcher Award

Posted on by Pencis

Ms. Dina Jiesisibieke | Reproductive Health | Best Researcher Award

Peking University Third Hospital | China

Author Profile

Scopus

Google Scholar

📌 DINA JIESISIBIEKE, M.D. CANDIDATE

🏥 CLINICAL MEDICINE AT PEKING UNIVERSITY THIRD HOSPITAL Peking University

🎓 EARLY ACADEMIC PURSUITS

Dina Jiesisibieke embarked on her medical journey at Peking University Third Hospital, where she has been pursuing a Doctor of Medicine (M.D.) degree since 2019. With an impressive GPA of 3.7/4.0, she has consistently demonstrated academic excellence and dedication to the field of clinical medicine. Her early academic years were marked by outstanding achievements, securing multiple scholarships and honors for her exceptional performance.

🏆 PROFESSIONAL ENDEAVORS

Beyond her academic pursuits, Dina has actively engaged in research and international exchange programs. In 2023, she participated in an exchange program at Mahidol University, where she gained hands-on experience in plastic surgery. This international exposure has broadened her clinical expertise and provided her with a global perspective on medical practices.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON REPRODUCTIVE HEALTH

Dina's research primarily focuses on reproductive medicine, specifically evaluating reproductive outcomes of conventional in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). Her work was recognized at the prestigious American Society for Reproductive Medicine (ASRM) conference in 2023, where she submitted a research abstract detailing her cohort study on reproductive outcomes.

🌍 IMPACT AND INFLUENCE

Dina's contributions extend beyond academic excellence, as she actively participates in scholarly discourse and medical research. Her involvement in clinical studies and international exchange programs positions her as an emerging leader in the medical field. Through her dedication to medical research and clinical training, she continues to inspire and set a benchmark for aspiring medical professionals.

📚 ACADEMIC CITATIONS

Her research has been recognized at a high level, with a conference abstract submitted to the American Society for Reproductive Medicine. This recognition highlights her growing influence in reproductive medicine and her commitment to contributing valuable insights to the medical community.

🏅 SCHOLARSHIPS AND AWARDS

Dina has been the recipient of numerous prestigious scholarships and awards, recognizing her academic excellence and dedication:

  • Merit Student of Peking University
  • Peking University Southwest Associated University Guan Yanhui Medical Education Scholarship (2019-2021)
  • Model Student of Academic Records of Peking University (2020-2024)
  • Peking University Weicai Pharmaceutical Scholarship (2021-2022)

🌟 LEGACY AND FUTURE CONTRIBUTIONS

As an aspiring physician, Dina Jiesisibieke is committed to advancing the field of clinical medicine and reproductive health. Her contributions to research, combined with her strong academic foundation and clinical experience, set the stage for a promising career in medicine. With continued dedication, she is poised to make a lasting impact in the field of reproductive medicine and beyond.

📑NOTABLE PUBLICATIONS 

"Prevalence of eye and adnexal disorders among elderly inmates in Taiwan prisons" 

  • Authors: C., Tsai, Chingyao , Z.L., Jiesisibieke, Zhu Liduzi , P., Tao, Ping , C., Chien, Chingwen , T., Tung, Taohsin
  • Journal: BMC Public Health
  • Year: 2024

Yong Xu | Cartilage Tissue | Best Researcher Award

Posted on by Pencis

Dr. Yong Xu | Cartilage Tissue | Best Researcher Award

Tongji University | China

Author Profile

Scopus

✨ XU YONG: A PIONEER IN TUMOR TREATMENT AND TISSUE REPAIR ✨

🎓 EARLY ACADEMIC PURSUITS

Xu Yong was born on May 29, 1991, in Fuzhou, Jiangxi, and pursued a career in medicine from an early age. He embarked on his academic journey at Tongji University School of Medicine, where he obtained his Bachelor of Clinical Medicine (2010-2015). With a keen interest in thoracic surgery and tissue engineering, he continued his education at Shanghai Pulmonary Hospital, earning a Master's Degree in Thoracic Surgery (2015-2018). His academic dedication led him to pursue a Ph.D. in Thoracic Surgery (2018-2021) at the same institution, where he developed expertise in tumor treatment and tissue repair.

🌟 PROFESSIONAL ENDEAVORS

Following his Ph.D., Xu Yong joined Shanghai Pulmonary Hospital as a Resident Physician (2021-2024), where he honed his clinical skills in thoracic surgery and tissue engineering. In August 2024, he transitioned to a research-focused role as a Special Associate Researcher at the Nuclear Industry 416 Hospital, Provincial Clinical Medical Research Center. His work in this position is instrumental in advancing innovative solutions for tracheal tissue engineering and regenerative medicine.

⚖️ CONTRIBUTIONS AND RESEARCH FOCUS ON CARTILAGE TISSUE

Xu Yong’s research primarily revolves around tissue engineering for cartilage regeneration, with a strong emphasis on functional tracheal reconstruction. His groundbreaking work introduced the "ring strategy", which enables the construction of bionic tracheal tissue with an alternating cartilage ring-connective tissue ring arrangement. This strategy successfully demonstrated long-term functional reconstruction of long-segment tracheal defects in rabbit models.

⚛️ MAJOR RESEARCH PROJECTS

Xu Yong has been the Principal Investigator (PI) in multiple prestigious projects, including:

  • Shanghai Science and Technology Rising Star Project (2024-2027): Focused on high-bionic tracheal tissue engineering (400,000 RMB).
  • Youth Talent Support Project (2023-2025): Dedicated to tracheal tissue engineering (300,000 RMB).
  • National Natural Science Foundation of China (2024-2026): Developing simulated tracheal tissue for large animal models (300,000 RMB).
  • Shanghai Natural Science Foundation (2022-2025): Advancing the construction of bioengineered trachea (200,000 RMB).

Additionally, he is a key participant in a major project funded by the National Natural Science Foundation of China (2,150,000 RMB), focusing on the precise matching of multiple cell types for bionic construction of long-segment trachea.

✨ IMPACT AND INFLUENCE

Xu Yong’s contributions have significantly influenced the field of tissue engineering and regenerative medicine, particularly in tracheal defect repair. His innovative biomimetic tracheal tissue construction has paved the way for improved clinical applications in treating long-segment tracheal defects. His research bridges the gap between basic science and clinical translation, offering promising therapeutic solutions for thoracic surgery.

🏆 ACADEMIC CITATIONS AND PUBLICATIONS

Xu Yong has an impressive publication record, contributing to over 30 SCI papers with a cumulative impact factor exceeding 300. His key achievements include:

  • 20 papers as first/co-first author
  • 14 papers as corresponding/co-corresponding author
  • 15 papers with an impact factor greater than 10
  • Highest single impact factor: 27.4

Notable journals where his research has been published:

  • Advanced Materials (ADV MATER)
  • Advanced Functional Materials (Adv. Funct. Mater.)
  • Advanced Science (Adv Sci.)
  • Composites Part B: Engineering (COMPOS PART B-ENG)
  • International Journal of Bioprinting (INT J BIOPRINTING)

Additionally, he holds over 10 patents related to tissue engineering and regenerative medicine.

🎬 LEGACY AND FUTURE CONTRIBUTIONS

Xu Yong’s pioneering efforts in tracheal tissue engineering and tumor treatment have established a new benchmark in the field. His ring strategy has set the foundation for future research in biomimetic tracheal reconstruction. Moving forward, he aims to:

  • Advance clinical translation of biomimetic tracheal tissue into human trials.
  • Explore novel biomaterials and tissue engineering scaffolds.
  • Collaborate on interdisciplinary projects integrating AI-driven biomaterial development.

His contributions will continue to shape the future of thoracic surgery, offering lifesaving solutions for patients with severe tracheal defects.

✨ CONCLUSION

Xu Yong is a trailblazer in regenerative medicine and thoracic surgery, whose dedication to tissue engineering and tracheal reconstruction has the potential to revolutionize the field. With a solid foundation in research, clinical expertise, and a vision for innovation, he is poised to make lasting contributions to modern medicine.

📑 NOTABLE PUBLICATIONS 

"Cartilage structure-inspired nanofiber-hydrogel composite with robust proliferation and stable chondral lineage-specific differentiation function to orchestrate cartilage regeneration for artificial tracheal construction" 

  • Authors: Y., Li, Yaqiang , X., Xun, Xiaowei , L., Duan, Liang , Y., Xu, Yong , H., Xia, Huitang
  • Journal: Bioactive Materials
  • Year: 2025

"Polydopamine-loaded microneedles for sequential tumor ablation and osteochondral regeneration" 

  • Authors: B., Lin, Bin , Y., Xu, Yong , B., Liang, Bing
  • Journal: Materials Letters
  • Year: 2025

"Copper hydrogen phosphate nanosheets functionalized hydrogel with tissue adhesive, antibacterial, and angiogenic capabilities for tracheal mucosal regeneration" 

  • Authors: P., Wang, Pengli , E., Gao, Erji , T., Wang, Tao , C., Yang, Chen , L., Duan, Liang
  • Journal: Journal of Nanobiotechnology
  • Year: 2024

"3D printing of Ceffe-infused scaffolds for tailored nipple-like cartilage development" 

  • Authors: J., Ding, Jinghao , C., Wei, Chuanzhi , Y., Xu, Yong , W., Dai, Wufei , R., Chen, Ru
  • Journal: BMC Biotechnology
  • Year: 2024

"Injectable and self-healing sulfated hyaluronic acid/gelatin hydrogel as dual drug delivery system for circumferential tracheal repair" 

  • Authors: Y., Yang, Yayan , X., Zhu, Xinsheng , X., Liu, Xuezhe , N., Song, Nan , Q., Feng, Qian
  • Journal: International Journal of Biological Macromolecules
  • Year: 2024

Junhua Wu | Tumor Gene Therapy | Excellence in Innovation

Posted on by Pencis

Prof Junhua Wu | Tumor Gene Therapy | Excellence in Innovation

Nanjing University | China

Author Profile

Scoups

Orcid ID

JUNHUA WU: PIONEERING RESEARCHER IN BIOMECHANICS AND ONCOLOGY 🔬

EARLY ACADEMIC PURSUITS 🎓

Junhua Wu embarked on his academic journey at Nanjing University (NJU), where he earned both his BSc in Life Sciences (1998–2002) and PhD in Life Sciences (2002–2007). His doctoral studies laid a strong foundation in molecular biology and biomechanics, equipping him with the expertise to make significant contributions to scientific research.

PROFESSIONAL ENDEAVORS 🏅

Following his graduation in June 2007, Junhua Wu remained at Nanjing University as a faculty member. His academic career has progressed steadily:

  • Lecturer (Since September 2007)
  • Associate Professor (Since December 2014)
  • Professor (Since December 2019)

He has received research funding from prestigious sources such as the National Natural Science Foundation of China, Key R&D Plan of Jiangsu Province, Natural Science Foundation of Jiangsu Province, and the Doctoral Program Fund of the Ministry of Education.

As an esteemed scholar, Professor Wu has published over 50 SCI papers in high-impact journals such as Nature Communications and holds 17 national invention patents. He has also contributed to academia through the compilation and translation of scientific monographs. His editorial roles include serving on the boards of Translational Oncology, Biocell, and Discovery Medicine.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR GENE THERAPY🔍

Professor Wu has made groundbreaking contributions in biomechanics, material science, and oncology. His research interests focus on protein hydrogels, tumorigenesis mechanisms, and novel cancer therapies.

1. Creation and Application of Hydrogels 💧

His work on protein hydrogels was a pioneering achievement in the field of biomechanics. He successfully demonstrated the ability to manipulate the mechanical properties of macromaterials by fine-tuning single protein molecules. His study, published in Nature Communications (2018), was a landmark contribution and has been cited 110 times.

His work was recognized in the 100th-anniversary special issue of international macromolecular science and was selected by the China Biomechanics Professional Committee as a key research advancement (2016–2018).

2. Mechanism of Tumorigenesis and Development 🧬

Professor Wu’s contributions to oncology include his exosome theory of sorafenib resistance in hepatocellular carcinoma, published in JECCR (2016). This study has been cited 113 times, influencing subsequent research on drug resistance in various cancers. His findings provided a new understanding of cancer cell communication and treatment resistance.

3. Innovative Cancer Therapies 💊

Professor Wu has developed novel strategies for cancer treatment, leading to over 20 invention patents and more than 30 high-impact SCI publications.

His research on mechanically stable peptide-graphene oxide hybrid hydrogels for drug delivery was highlighted as a Web of Science highly cited paper (Top 1% globally). This work demonstrated precise drug release mechanisms and was recognized for its potential to revolutionize targeted cancer therapy.

His “Trojan Horse” strategy for oncolytic virus delivery represents another major breakthrough. Published in JECCR (2019), this method involves using graphene nanoflakes to enhance viral delivery to tumors, significantly improving therapeutic outcomes.

IMPACT AND INFLUENCE 🌍

Professor Wu’s research has had a profound impact on multiple disciplines, including biomechanics, biomaterials, and oncology. His pioneering studies have inspired global researchers, with scholars from institutions such as the University of Wisconsin-Milwaukee drawing on his ideas for their work in Nature Communications, Science Advances, and PRL.

His cancer therapy innovations have been widely cited and applied by leading oncologists and material scientists. His findings have been positively reviewed and referenced in major scientific publications, solidifying his reputation as a thought leader in the field.

ACADEMIC CITATIONS 📑

Professor Wu’s work has received extensive recognition, accumulating hundreds of citations. Some notable statistics include:

  • 110+ citations for his 2018 Nature Communications paper on protein hydrogels.
  • 113+ citations for his 2016 JECCR paper on exosome-mediated drug resistance.
  • 122+ citations for his 2015 Nanoscale paper on peptide-graphene oxide hybrid hydrogels.

LEGACY AND FUTURE CONTRIBUTIONS 🚀

Professor Junhua Wu’s legacy is defined by his interdisciplinary approach, bridging biomechanics, biomaterials, and cancer therapy. His innovative methodologies continue to shape biomedical engineering and oncology research.

Moving forward, he aims to:

  • Expand the applications of protein hydrogels for regenerative medicine and tissue engineering.
  • Advance tumor microecology studies to develop next-generation immunotherapies.
  • Refine oncolytic virus-based cancer treatments, enhancing their efficacy and clinical applications.

CONCLUSION 🏆

Junhua Wu stands as a pioneering figure in his fields of expertise. His work has redefined our understanding of mechanobiology and cancer treatment, earning him a place among the most influential scientists in modern biomedical research. His dedication to innovation ensures that his impact will continue to resonate for years to come.

NOTABLE PUBLICATIONS 📑

"SENP3 inhibition suppresses hepatocellular carcinoma progression and improves the efficacy of anti-PD-1 immunotherapy" 

  • Authors: P., Wang, Peng , J., Qiu, Jiannan , Y., Fang, Yuan , J., Wu, Junhua , C., Jiang,
  • Journal: Chunping Cell Death and Differentiation
  • Year: 2025

"Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy" 

  • Authors: K., Liu, Kua , L., Kong, Lingkai , H., Cui, Huawei , C., Jiang, Chunping , J., Wu, Junhua
  • Journal: Cell Reports Medicine
  • Year: 2024

"CuET overcomes regorafenib resistance by inhibiting epithelial-mesenchymal transition through suppression of the ERK pathway in hepatocellular carcinoma" 

  • Authors: D., Ma, Ding , S., Liu, Shuwen , K., Liu, Kua , J., Wu, Junhua , C., Jiang, Chunping
  • Journal: Translational Oncology
  • Year: 2024

"Toward Practical Applications of Engineered Living Materials with Advanced Fabrication Techniques" 

  • Authors: C., Lu, Chenjing , Y., Huang, Yaying , J., Cui, Jian , Y., Cao, Yi , S., Yin, Sheng
  • Journal: ACS Synthetic Biology
  • Year: 2024

"Structurally and mechanically tuned macroporous hydrogels for scalable mesenchymal stem cell-extracellular matrix spheroid production " 

  • Authors: S., Yin, Sheng , H., Wu, Haipeng , Y., Huang, Yaying , W., Wang, Wei , Y., Cao, Yi
  • Journal: Proceedings of the National Academy of Sciences of the United States of America
  • Year: 2024

Kang Yang | Metabolic Disorders | Best Researcher Award

Posted on by Pencis

Dr. Kang Yang | Metabolic Disorders | Best Researcher Award

Northern Jiangsu People's Hospital affiliated with Yangzhou University | China

Author Profile

Scopus

Orcid Id

EARLY ACADEMIC PURSUITS 🎓

Kang Yang embarked on his academic journey at Shandong First Medical University, where he pursued a Bachelor of Medicine (BM) in 2017 under the mentorship of Professor Jianhong Qi. His early interest in sports medicine and rehabilitation laid a strong foundation for his future contributions in the field.

Building on this, he further honed his expertise at Yangzhou University, obtaining a Master of Medicine (MM) in 2020 under the guidance of Professor Xianghe Chen. His postgraduate studies deepened his understanding of rehabilitation techniques, patient care, and innovative treatments in sports medicine.

PROFESSIONAL ENDEAVORS 💼

As a rehabilitation physician and therapist, Kang Yang is committed to enhancing the quality of life for patients recovering from injuries, surgeries, and physical impairments. His work integrates advanced rehabilitation methodologies with patient-centered approaches to ensure effective recovery and functional restoration.

Throughout his career, he has actively contributed to both clinical practice and academic research, focusing on rehabilitation strategies tailored for athletes and individuals with musculoskeletal disorders.

CONTRIBUTIONS AND RESEARCH FOCUS ON METABOLIC DISORDERS🔬

Kang Yang’s research primarily revolves around sports medicine and rehabilitation medicine. His investigations explore:

  • Innovative rehabilitation techniques for sports-related injuries.
  • Physiological and biomechanical adaptations in long-distance runners and athletes.
  • Post-injury recovery protocols aimed at optimizing healing and preventing re-injury.

His dedication to research has led to significant advancements in sports rehabilitation, with a particular focus on marathon runners and endurance athletes.

IMPACT AND INFLUENCE 🔍

Kang Yang's contributions extend beyond clinical settings. His work has influenced:

  • Rehabilitation strategies for sports professionals.
  • Medical education, through his involvement in teaching and mentoring young medical students.
  • Public awareness on the importance of injury prevention and rehabilitation in sports.

His clinical expertise and research have helped shape modern rehabilitation protocols, making a positive impact on both patient outcomes and medical practices.

ACADEMIC CITATIONS AND RECOGNITION 🏆

Kang Yang’s academic excellence has been recognized through multiple prestigious awards:

  • Special Prize (2018) & First Prize (2019) at the Jiangsu Sports Graduate Innovation Forum.
  • 2019 National Scholarship for Postgraduates (China).
  • First-class academic scholarship from Yangzhou University.

These accolades highlight his commitment to academic excellence, research innovation, and contributions to the medical community.

LEGACY AND FUTURE CONTRIBUTIONS🏰

Looking ahead, Kang Yang aims to:

  • Expand his research on sports rehabilitation and injury prevention.
  • Develop advanced therapeutic protocols for athletes and individuals recovering from physical trauma.
  • Collaborate with international experts to enhance rehabilitation medicine globally.
  • Continue mentoring students and young professionals in the field of rehabilitation sciences.

His unwavering passion and dedication position him as a future leader in the evolving landscape of sports medicine and rehabilitation.

BEYOND MEDICINE: PERSONAL INTERESTS 📚

Outside of his professional life, Kang Yang enjoys:

  • Long-distance running and marathons, reflecting his deep understanding of sports medicine from both a theoretical and practical perspective.
  • Reading, staying updated with the latest medical advancements and broadening his intellectual horizons.

NOTABLE PUBLICATIONS📑

"Exercise alleviates renal interstitial fibrosis by ameliorating the Sirt1-mediated TGF-β1/Smad3 pathway in T2DM mice" 

  • Authors: X., Chen, Xianghe , X., Zeng, Xinyu , X., Qiu, Xiao , X., Zhou, Xiangxiang , K., Yang, Kang
  • Journal: Endocrine Connections
  • Year: 2024

Zafran Khan | Tuberculosis Researcher | Editorial Board Member

Posted on by Pencis

Mr. Zafran Khan | Tuberculosis | Editorial Board Member

University of Calgary | Pakisthan

Author Profile

Google Scholar

Orcid ID

EARLY ACADEMIC PURSUITS:

ZAFRAN KHAN initiated his academic journey at the University of Swat (UOS) in Swat, Pakistan, where he pursued a Bachelor of Science (Hons) in Microbiology from 2012 to 2016. During this period, he conducted research on the "Incidence of HCV in the general population of District Swat, Pakistan," showcasing an early interest in infectious diseases and molecular biology.

PROFESSIONAL ENDEAVORS:

Following his undergraduate studies, ZAFRAN KHAN ventured into higher education at the University of Chinese Academy of Sciences (UCAS) in Beijing, China. Here, he enrolled as a Master student in Biochemistry and Molecular Biology from September 2018 to August 2019. His coursework covered diverse topics, including Genomics, Immunology, Biochemistry, and Molecular Biology, laying a solid foundation for his subsequent research pursuits.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUBERCULOSIS

ZAFRAN KHAN's notable research contributions are evident during his tenure as a Master's Full-time Research Candidate at the State Key Laboratory of Respiratory Infectious Disease (GIBH) in Guangzhou, China, from August 2019 to August 2021. His primary research focus encompassed Mycobacterium tuberculosis resistance mechanisms, novel drug targets, docking, molecular dynamic simulation, and vaccine and drug designing. Noteworthy projects include the identification of resistance mechanisms associated with prothionamide and amikacin in Mycobacterium tuberculosis clinical isolates.

IMPACT AND INFLUENCE:

ZAFRAN KHAN's work holds significant implications for understanding and combating tuberculosis, a global health concern. His efforts in exploring unexplored resistance mechanisms and conducting molecular detection of anti-tubercular resistance in clinical isolates contribute to the broader scientific community's knowledge base. The impact of his research extends beyond borders, as evidenced by his involvement in international conferences and workshops.

ACADEMIC CITES:

ZAFRAN KHAN's academic journey is marked by a commitment to excellence, exemplified by his active participation in international conferences and workshops. This exposure has likely contributed to his knowledge enrichment and the incorporation of global perspectives into his research.

LEGACY AND FUTURE CONTRIBUTIONS:

ZAFRAN KHAN has established a legacy of dedication and proficiency in the field of Microbiology and Molecular Biology. His early research on HCV in Swat and subsequent work on tuberculosis resistance mechanisms showcase a commitment to addressing critical health challenges. As he progresses in his academic and research journey, ZAFRAN KHAN is poised to make further contributions to the scientific community, leaving a lasting legacy in the realm of infectious diseases and immunity.

Notable Publications

Guillain-Barre syndrome: An autoimmune disorder post-COVID-19 vaccination?  2022(9)

Cold stress-induced seed germination and biosynthesis of polyphenolics content in medicinally important Brassica rapa 2022(8)

Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; a comprehensive review 2022(7)